FRANKFURT, GERMANY
Xeomin cleared for pediatric upper limb spasticity in cerebral palsy
- Sponsor
- Merz Therapeutics
- Drug
- Xeomin · incobotulinumtoxinA
- Indication
- Upper-limb spasticity in pediatric patients aged 2 and older with cerebral palsy
FDA approved Merz Therapeutics' Xeomin (incobotulinumtoxinA) for the treatment of upper-limb spasticity in pediatric patients aged 2 and older with cerebral palsy. Xeomin was previously approved for adult upper-limb spasticity in 2010; this label expansion extends the indication into the largest population for which upper-limb spasticity intervention is prescribed.
Read original at drugs.com ↗Drug Watch — recent news on Xeomin
- Procedures like Botox are booming in Ontario. But not all doctors, nurses agree on how they should be provided - CBC
- Planning to get Botox? Here’s how the College of Nurses Ontario is changing its guidance - CBC
- Procedures like Botox are booming in Ontario. But not all doctors, nurses agree on how they should be provided - unpublished.ca
- My Crepey Arms Are Noticeably Firm After Just 4 Weeks of Using This Lotion From the Makers of Botox - instyle.com
- Procedures like Botox are booming in Ontario. But not all doctors, nurses agree on how they should be provided - CBC
Sponsor Watch — recent news on Merz Therapeutics
- SpaceX Lands With a Thud
- J&J's Innovative Medicine Unit Proves Its Resilience in Q2
- AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
- Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)